These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Cellular and molecular neuropathology of schizophrenia: new directions from developmental neurobiology. Turner EE; Fedtsova N; Jeste DV Schizophr Res; 1997 Oct; 27(2-3):169-80. PubMed ID: 9416646 [TBL] [Abstract][Full Text] [Related]
24. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Jann MW Pharmacotherapy; 2004 Dec; 24(12):1759-83. PubMed ID: 15585443 [TBL] [Abstract][Full Text] [Related]
25. Searching genetic risk factors for schizophrenia and bipolar disorder: learn from the past and back to the future. Alaerts M; Del-Favero J Hum Mutat; 2009 Aug; 30(8):1139-52. PubMed ID: 19626716 [TBL] [Abstract][Full Text] [Related]
31. Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Meyer U; Feldon J Behav Brain Res; 2009 Dec; 204(2):322-34. PubMed ID: 19154759 [TBL] [Abstract][Full Text] [Related]
32. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197 [TBL] [Abstract][Full Text] [Related]
33. Postmortem neurochemistry in schizophrenia. Bracha HS; Kleinman JE Psychiatr Clin North Am; 1986 Mar; 9(1):133-41. PubMed ID: 2421270 [TBL] [Abstract][Full Text] [Related]
34. Gaba blockade, dopamine and schizophrenia: experimental activation of the mesolimbic system. Stevens JR Int J Neurol; 1975; 10(1-4):115-27. PubMed ID: 1237474 [No Abstract] [Full Text] [Related]
35. Schizophrenia: diverse approaches to a complex disease. Sawa A; Snyder SH Science; 2002 Apr; 296(5568):692-5. PubMed ID: 11976442 [TBL] [Abstract][Full Text] [Related]
36. The effects of manganese on glutamate, dopamine and gamma-aminobutyric acid regulation. Fitsanakis VA; Au C; Erikson KM; Aschner M Neurochem Int; 2006; 48(6-7):426-33. PubMed ID: 16513220 [TBL] [Abstract][Full Text] [Related]
37. Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia. Williams M Curr Opin Investig Drugs; 2003 Jan; 4(1):31-6. PubMed ID: 12625025 [TBL] [Abstract][Full Text] [Related]
39. [Do the glutamate excitotoxicity theory and potential free radicals implication in schizophrenia aetiopathogenesis provide a new enlightenment to links between: genome, environment and biology in the determinism of that disorder?]. Nguimfack Mbodie PC Encephale; 2002; 28(2):147-53. PubMed ID: 11972141 [TBL] [Abstract][Full Text] [Related]
40. Recent advances in postmortem pathology and neurochemistry in schizophrenia. Dean B; Boer S; Gibbons A; Money T; Scarr E Curr Opin Psychiatry; 2009 Mar; 22(2):154-60. PubMed ID: 19553869 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]